Haverford Financial Services Inc. cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 9.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 29,438 shares of the medical instruments supplier’s stock after selling 2,917 shares during the period. Becton, Dickinson and accounts for about 2.3% of Haverford Financial Services Inc.’s holdings, making the stock its 21st biggest position. Haverford Financial Services Inc.’s holdings in Becton, Dickinson and were worth $5,768,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Guardian Life Insurance Co. of America increased its holdings in shares of Becton, Dickinson and by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after buying an additional 6 shares during the last quarter. Family Firm Inc. increased its holdings in shares of Becton, Dickinson and by 0.5% during the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC increased its holdings in shares of Becton, Dickinson and by 0.4% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after buying an additional 6 shares during the last quarter. Wellington Shields & Co. LLC increased its holdings in shares of Becton, Dickinson and by 0.3% during the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after buying an additional 7 shares during the last quarter. Finally, Northstar Group Inc. increased its holdings in shares of Becton, Dickinson and by 0.3% during the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after buying an additional 9 shares during the last quarter. Institutional investors own 87.91% of the company’s stock.

In related news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the sale, the insider now owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

Shares of Becton, Dickinson and Company (BDX) opened at $224.23 on Friday. Becton, Dickinson and Company has a twelve month low of $161.29 and a twelve month high of $227.50. The stock has a market capitalization of $51,119.57, a price-to-earnings ratio of 23.63, a P/E/G ratio of 1.76 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The firm had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same period in the prior year, the firm earned $2.12 EPS. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. equities analysts anticipate that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a $0.75 dividend. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a yield of 1.34%. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s dividend payout ratio is currently 62.80%.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/11/24/haverford-financial-services-inc-has-5-77-million-holdings-in-becton-dickinson-and-company-bdx.html.

A number of research firms have recently commented on BDX. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Royal Bank Of Canada restated a “hold” rating and set a $210.00 price objective on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Tuesday, October 31st. Cowen Inc restated a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Barclays PLC restated an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $217.08.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.